Cencora, Inc.
HealthcareNYSE:COR · New York Stock Exchange
+$0.68 today
Vol 0.52M · Avg 1.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
103.1%
avg 94.8%
ROIC
13.2%
avg 11.8%
ROA
2.0%
avg 1.5%
Analysis
ROE is currently the strongest return metric at 103.1% versus its period average of 94.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Mauch | President, Chief Executive Officer & Director | $6.26M | — | 59 | $65,393.00 | 0.03% |
James F. Cleary Jr. | Executive Vice President & Chief Financial Officer | $2.72M | — | 63 | $165,766.35 | 0.09% |
Elizabeth S. Campbell | Executive Vice President & Chief Legal Officer | $2.28M | — | 51 | $36,547.67 | 0.02% |
Silvana Battaglia | Executive Vice President & Chief Human Resources Officer | $1.96M | — | 58 | $27,238.81 | 0.01% |
Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | — | — | — | — | — |
François Mandeville | Executive Vice President and Chief Strategy and M&A Officer | — | — | — | — | — |
Juan Guerra | EVP & President of International Business Group | — | — | — | — | — |
Lazarus Krikorian | Senior Vice President, Chief Accounting Officer & Corporate Controller | — | — | 61 | $3,936.00 | <0.01% |
Pawan Singh Verma | Executive Vice President and Chief Data & Information Officer | — | — | 49 | $3,948.00 | <0.01% |
Richard Tremonte | EVP and President of U.S. Pharmaceuticals & Animal Health | — | — | — | $28,762.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.07M
Sells
19
$41.55M
Net Sentiment
$40.48M
Net selling
Most Active
Mauch Robert P.
10 transactions
1–10 of 20
Analysis
Insiders reported 1 buys worth $1.07M and 19 sells worth $41.55M over the last 12 months. That adds up to net selling of $40.48M. Mauch Robert P. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.6% | +7.2% (15yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | +0.6% | +7.0% (15yr)8 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.6% over three years. Forward estimates point to Revenue at +7.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.86B
Galenica AG
GALNF
$5.73B
McKesson Europe AG
CAKFY
$5.37B
Sugi Holdings Co.,Ltd.
SGIPF
$2.95B
Patterson Companies, Inc.
PDCO
$2.77B
Alfresa Holdings Corporation
ARHCF
$2.16B
MakingORG, Inc.
CQCQ
$26.66M
MEDirect Latino, Inc.
MLTO
$1,700.00
TGC Ventures International, Inc.
TGVN
$120.00
Covetrus, Inc.
CVET
$0.00
Who manages COR?
Cencora, Inc. (COR) lists 10 active executives. The top listed executive is Elizabeth S. Campbell, Executive Vice President & Chief Legal Officer.
Are COR insiders buying or selling?
Recent insider activity shows net selling of $91.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.